4//SEC Filing
Voss Advisors GP, LLC 4
Accession 0000921895-25-003156
CIK 0001420565other
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 5:30 PM ET
Size
15.6 KB
Accession
0000921895-25-003156
Insider Transaction Report
Form 4
Voss Capital, LP
10% Owner
Transactions
- Purchase
Common Stock, $0.001 par value
2025-11-14$1.22/sh+104,183$127,593→ 926,441 total(indirect: By: Voss Value Master Fund, L.P.)
Holdings
- 500,000(indirect: By: Voss Value-Oriented Special Situations Fund, L.P.)
Common Stock, $0.001 par value
Transactions
- Purchase
Common Stock, $0.001 par value
2025-11-14$1.22/sh+104,183$127,593→ 926,441 total(indirect: By: Voss Value Master Fund, L.P.)
Holdings
- 500,000(indirect: By: Voss Value-Oriented Special Situations Fund, L.P.)
Common Stock, $0.001 par value
Voss Value Master Fund, LP
10% Owner
Transactions
- Purchase
Common Stock, $0.001 par value
2025-11-14$1.22/sh+104,183$127,593→ 926,441 total(indirect: By: Voss Value Master Fund, L.P.)
Holdings
- 500,000(indirect: By: Voss Value-Oriented Special Situations Fund, L.P.)
Common Stock, $0.001 par value
Voss Advisors GP, LLC
10% Owner
Transactions
- Purchase
Common Stock, $0.001 par value
2025-11-14$1.22/sh+104,183$127,593→ 926,441 total(indirect: By: Voss Value Master Fund, L.P.)
Holdings
- 500,000(indirect: By: Voss Value-Oriented Special Situations Fund, L.P.)
Common Stock, $0.001 par value
Cocke Travis W.
10% Owner
Transactions
- Purchase
Common Stock, $0.001 par value
2025-11-14$1.22/sh+104,183$127,593→ 926,441 total(indirect: By: Voss Value Master Fund, L.P.)
Holdings
- 500,000(indirect: By: Voss Value-Oriented Special Situations Fund, L.P.)
Common Stock, $0.001 par value
Footnotes (4)
- [F1]This Form 4 is filed jointly by Voss Value Master Fund, LP ("Voss Value Master Fund"), Voss Value-Oriented Special Situations Fund, LP ("Voss Value-Oriented Special Situations Fund"), Voss Advisors GP, LLC ("Voss GP"), Voss Capital, LP ("Voss Capital") and Travis W. Cocke (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F2]Securities owned directly by Voss Value Master Fund. Voss GP, as the general partner of Voss Value Master Fund, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund. Voss Capital, as the investment manager of Voss Value Master Fund, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund. Mr. Cocke, as the managing member of Voss Capital and Voss GP, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund.
- [F3]Securities owned directly by Voss Value-Oriented Special Situations Fund. Voss GP, as the general partner of Voss Value-Oriented Special Situations Fund, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund. Voss Capital, as the investment manager of Voss Value-Oriented Special Situations Fund, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund. Mr. Cocke, as the managing member of Voss Capital and Voss GP, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund.
- [F4]Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.1800 to $1.2500, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Documents
Issuer
Rein Therapeutics, Inc.
CIK 0001420565
Entity typeother
Related Parties
1- filerCIK 0001798309
Filing Metadata
- Form type
- 4
- Filed
- Nov 17, 7:00 PM ET
- Accepted
- Nov 18, 5:30 PM ET
- Size
- 15.6 KB